BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33579736)

  • 1. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
    Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
    [No Abstract]   [Full Text] [Related]  

  • 2. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand.
    Kim HS; Kim-Schulze S; Kim DW; Kaufman HL
    Cancer Res; 2009 Nov; 69(21):8516-25. PubMed ID: 19843856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.
    Lu SC; Hansen MJ; Hemsath JR; Parrett BJ; Zell BN; Barry MA
    Hum Gene Ther; 2022 Mar; 33(5-6):250-261. PubMed ID: 34731019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
    Zhao Y; Croft M
    Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
    Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
    Seclì L; Infante L; Nocchi L; De Lucia M; Cotugno G; Leoni G; Micarelli E; Garzia I; Avalle L; Sdruscia G; Troise F; Allocca S; Romano G; Scarselli E; D'Alise AM
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37117006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
    Kanagavelu S; Termini JM; Gupta S; Raffa FN; Fuller KA; Rivas Y; Philip S; Kornbluth RS; Stone GW
    PLoS One; 2014; 9(2):e90100. PubMed ID: 24587225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
    Powell KL; Stephens AS; Ralph SJ
    Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.
    Sluijter BJ; van den Hout MF; Stam AG; Lougheed SM; Suhoski MM; van den Eertwegh AJ; van den Tol MP; van Leeuwen PA; Meijer S; Scheper RJ; June CH; de Gruijl TD; Santegoets SJ
    Clin Immunol; 2010 Nov; 137(2):221-33. PubMed ID: 20708974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
    Tenesaca S; Vasquez M; Alvarez M; Otano I; Fernandez-Sendin M; Di Trani CA; Ardaiz N; Gomar C; Bella A; Aranda F; Medina-Echeverz J; Melero I; Berraondo P
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
    Zamarin D; Holmgaard RB; Subudhi SK; Park JS; Mansour M; Palese P; Merghoub T; Wolchok JD; Allison JP
    Sci Transl Med; 2014 Mar; 6(226):226ra32. PubMed ID: 24598590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
    Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
    Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of viral oncolysis and tumor-specific immunity to control established tumors.
    Chuang CM; Monie A; Wu A; Pai SI; Hung CF
    Clin Cancer Res; 2009 Jul; 15(14):4581-8. PubMed ID: 19584165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
    Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
    Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.
    Staib C; Kisling S; Erfle V; Sutter G
    J Gen Virol; 2005 Jul; 86(Pt 7):1997-2006. PubMed ID: 15958679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.